# OnCo record neoadjuvant-cemiplimab-cscc (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/neoadjuvant-cemiplimab-cscc/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "neoadjuvant-cemiplimab-cscc", "NCT04154943" ;
  schema:name "Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma"@en ;
  schema:alternateName "Gross neoadjuvant cemiplimab study"@en, "neoadjuvant cemiplimab in cutaneous squamous cell carcinoma"@en ;
  schema:description "Giving the immunotherapy before the operation left no living cancer cells in the removed specimen in half of the patients. For tumours that would otherwise cost someone an eye, an ear or part of the face, that changes what the operation has to take."@en ;
  schema:url <https://onco.cc/trials/neoadjuvant-cemiplimab-cscc/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04154943>, <https://doi.org/10.1056/NEJMoa2209813>, <https://pubmed.ncbi.nlm.nih.gov/36094839/> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/advanced-cutaneous-scc/>, <https://onco.cc/cancers/skin-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:companies <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/sanofi/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/surgical-margins-keratinocyte-cancer/> ;
  onco:trials <https://onco.cc/trials/empower-cscc-1/>, <https://onco.cc/trials/c-post/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022/> .